Rimonabant(Acomplia) is an anti-obesity drug that is marketed under the trade name Acomplia that is manufactured by the French pharmaceutical company, Sanofi-Aventis. The availability of Rimonabant (Acomplia) has been widely anticipated as studies have shown it to be effective in not only weight lose but with stopping smoking as well.

Rimonabant (Accomplia) works by blocking one of two receptors, the CB1 receptor, which is part of the Endocannabinoid System. The Endocannabinoid System is thought to play an important role in regulating food intake and energy expenditure from the body.

Studies have shown that the CB1 receptors are present in the body’s fat cells particularly those located in the part of the brain called the hypothalamus, which controls appetite. Cannabinoids attach themselves to the CB1 receptors, which then signal the body to take in more food.

Rimonabant (Accomplia) works differently than other diet pills in that it specifically targets and blocks the CB1 receptors, which help regulate the Endocannabinoid System resulting in less desire/cravings for food. This same process also helps to reduce tobacco dependence. Blocking of the CB1 receptors also has been shown to reduce cardiovascular risk by lowering blood pressure, cholesterol and blood sugar levels.

Rimonabant (Acomplia) is manufactured in 20 mg tablets and is available by prescription only. The prescribed dose is 1 tablet per day taken before breakfast. Rimonabant (Acomplia) has been available since June 2006 in the UK and will soon be available in Ireland, Germany, Finland and Denmark. Sanofi has plans to market Rimonabant under the trade name Zimulti when it receives FDA approval in the United States.